Next Article in Journal
The Role of Vesicle Trafficking Defects in the Pathogenesis of Prion and Prion-Like Disorders
Next Article in Special Issue
Impact of HLA-DR Antigen Binding Cleft Rigidity on T Cell Recognition
Previous Article in Journal
Ethionamide Preconditioning Enhances the Proliferation and Migration of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells
Previous Article in Special Issue
IL-21 in Homeostasis of Resident Memory and Exhausted CD8 T Cells during Persistent Infection

Treg Enhancing Therapies to Treat Autoimmune Diseases

Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, VIC 3168, Australia
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(19), 7015;
Received: 30 August 2020 / Revised: 16 September 2020 / Accepted: 22 September 2020 / Published: 23 September 2020
(This article belongs to the Special Issue Recent Advances in T Cell Immunity)
Regulatory T cells (Tregs) are a small yet critical subset of CD4+ T cells, which have the role of maintaining immune homeostasis by, for example, regulating self-tolerance, tumor immunity, anti-microbial resistance, allergy and transplantation rejection. The suppressive mechanisms by which Tregs function are varied and pleiotropic. The ability of Tregs to maintain self-tolerance means they are critical for the control and prevention of autoimmune diseases. Irregularities in Treg function and number can result in loss of tolerance and autoimmune disease. Restoring immune homeostasis and tolerance through the promotion, activation or delivery of Tregs has emerged as a focus for therapies aimed at curing or controlling autoimmune diseases. Such therapies have focused on the Treg cell subset by using drugs to suppress T effector cells and promote Tregs. Other approaches have trialed inducing tolerance by administering the autoantigen via direct administration, by transient expression using a DNA vector, or by antigen-specific nanoparticles. More recently, cell-based therapies have been developed as an approach to directly or indirectly enhance Treg cell specificity, function and number. This can be achieved indirectly by transfer of tolerogenic dendritic cells, which have the potential to expand antigen-specific Treg cells. Treg cells can be directly administered to treat autoimmune disease by way of polyclonal Tregs or Tregs transduced with a receptor with high affinity for the target autoantigen, such as a high affinity T cell receptor (TCR) or a chimeric antigen receptor (CAR). This review will discuss the strategies being developed to redirect autoimmune responses to a state of immune tolerance, with the aim of the prevention or amelioration of autoimmune disease. View Full-Text
Keywords: Treg; Treg therapy; cell-based therapy; autoimmunity; autoimmune disease Treg; Treg therapy; cell-based therapy; autoimmunity; autoimmune disease
Show Figures

Figure 1

MDPI and ACS Style

Eggenhuizen, P.J.; Ng, B.H.; Ooi, J.D. Treg Enhancing Therapies to Treat Autoimmune Diseases. Int. J. Mol. Sci. 2020, 21, 7015.

AMA Style

Eggenhuizen PJ, Ng BH, Ooi JD. Treg Enhancing Therapies to Treat Autoimmune Diseases. International Journal of Molecular Sciences. 2020; 21(19):7015.

Chicago/Turabian Style

Eggenhuizen, Peter J., Boaz H. Ng, and Joshua D. Ooi 2020. "Treg Enhancing Therapies to Treat Autoimmune Diseases" International Journal of Molecular Sciences 21, no. 19: 7015.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop